Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline reveals FDA’s authorisation of Votrient

GlaxoSmithKline reveals FDA’s authorisation of Votrient

21st October 2009

GlaxoSmithKline drug Votrient (pazopanib) – which is intended for use in patients with renal cell carcinoma (RCC) – has been approved by the Food and Drug Administration (FDA).

Votrient is a once-daily oral medication and an angiogenesis inhibitor that may help prevent the growth of new blood vessels, contributing to the hindering of kidney cancer tumors’ growth.

The FDA’s decision comes after a phase III clinical trial showed that Votrient reduces the risk of tumour progression or death by 54 per cent compared to a placebo, regardless of prior treatment.

Paolo Paoletti, senior vice-president of GlaxoSmithKline’s oncology research and development unit, explained that RCC is “highly resistant” to chemotherapy.

“Votrient will join existing targeted therapies to provide physicians with a new oral treatment option to their patients with advanced renal cell cancer,” he added.

GlaxoSmithKline this week announced that it will join forces with the Holland-based biopharmaceutical firm Prosensa to develop and commercialise therapies for Duchenne muscular dystrophy.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.